Mustang Bio, Inc.
MBIO
$1.09
-$0.08-6.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -57.31% | -33.98% | -34.87% | -21.37% | -20.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -75.25% | -65.03% | -53.81% | -45.59% | -33.39% |
| Operating Income | 75.25% | 65.03% | 53.81% | 45.59% | 33.39% |
| Income Before Tax | 69.47% | 62.61% | 55.19% | 46.12% | 33.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.47% | 62.61% | 55.19% | 46.12% | 33.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.47% | 62.61% | 55.19% | 46.12% | 33.44% |
| EBIT | 75.25% | 65.03% | 53.81% | 45.59% | 33.39% |
| EBITDA | 75.68% | 65.20% | 53.63% | 45.37% | 33.46% |
| EPS Basic | 85.81% | 77.94% | 67.56% | 51.90% | 39.11% |
| Normalized Basic EPS | 88.38% | 79.44% | 66.64% | 49.82% | 37.16% |
| EPS Diluted | 85.81% | 77.94% | 67.56% | 51.90% | 39.11% |
| Normalized Diluted EPS | 88.38% | 79.44% | 66.64% | 49.82% | 37.16% |
| Average Basic Shares Outstanding | 254.02% | 151.46% | 64.34% | 19.22% | 11.96% |
| Average Diluted Shares Outstanding | 254.02% | 151.46% | 64.34% | 19.22% | 11.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |